Re2O and DermaCell: what to confirm for hADM skin boosters in consultation

How do Re2O and DermaCell differ?

When you research skin boosters and meet Re2O or DermaCell, the explanation can feel unfamiliar. Unlike Rejuran or Juvelook, a single ingredient name does not jump out first, and the phrase "human dermal–derived" is attached—so it is hard to know what to verify.

The core difference is that the source material did not come from your own body. Unlike autologous procedures that start from your own fat or blood—such as SVF or PRF—Re2O and DermaCell use human acellular dermal matrix (hADM) as the source material. That adds one more confirmation layer: where the material came from and what process it went through. Cellinique Clinic — a 10-minute walk from Apgujeong Station, at 228 Dosan-daero — summarizes the order we actually walk through in consultation.

3-line summary

1. Re2O and DermaCell are skin boosters that use human dermal (hADM)–derived components. Their source-material family is different from SVF and PRF, which start from your own tissue.
2. That is why the checklist grows to five items — exact product name, source-material origin, donor screening and testing information, processing and storage, and lot traceability records.
3. The consent form does not promise results; it fixes the scope of the material and the process. Your first check is whether the product name and treatment areas match across the verbal explanation and the paperwork.

1. Start by separating source-material families

Under the single words "regeneration" or "skin booster," materials that start from different places are often grouped together. Once you can separate them, the questions you should ask in consultation fall into place on their own.

Family	Examples	Starting material	Extra items to confirm
Human dermal–derived	Re2O · DermaCell	Human dermal matrix (hADM)	Donor screening and testing, processing, lot traceability
Autologous fat–derived	SVF	Your own fat	Donor-site recovery, processing method
Autologous blood–derived	PRF	Your own blood	Blood draw volume, processing steps
Synthetic / purified ingredients	Rejuran (PN) · Juvelook (PLA+HA)	Manufactured ingredients	Approved or labeled use purpose

In the table, only the first row needs donor information. That item does not appear for the other three families. How each family changes consultation is covered further in our PRF · SVF source-material guide.

When two options are offered in one visit, write the family name next to each product before you compare recovery or cost. Mixing a human dermal–derived option with an autologous option under one "regeneration" label is the most common reason expectations and documents later fail to match.

2. Confirm the scope of the word hADM

The phrase "human dermal–derived" alone does not mean that source material, processing level, intended use, and product classification are the same. Products differ. In consultation, first lock the exact product name and manufacturing or supply information, then confirm source material and treatment areas separately.

Fact check — evidence level: regulator definition document

The U.S. FDA defines human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient as HCT/P, and lists examples such as bone, skin, cornea, and ligaments. Human dermal material is also handled within this category.
This definition belongs to the U.S. regulatory framework; authorization and indications for products used in Korea should be confirmed with Korean official information and the actual product documents. (Source: FDA, Tissue & Tissue Products)

Product-level information for Re2O is on the Re2O treatment page, and DermaCell is on the DermaCell treatment page. Even so, individual product pages do not replace the consent form — confirm the documents for the material that will actually be used this time.

If marketing language uses "human dermal," "acellular matrix," or "regenerative booster" interchangeably, ask which legal or catalog name appears on the label and lot paperwork. The phrase you hear in conversation and the name on the lot record should be the same string, not two close synonyms.

3. Treat donor screening and testing as "information you can receive"

For human dermal–derived materials, the question most often skipped is here. Instead of accepting "it is safe," ask what information can be provided.

Fact check — evidence level: regulator requirements document

The U.S. FDA states that tissue establishments are required to screen and test donors and maintain written procedures and records to reduce the risk of communicable disease transmission. Donor-testing requirements are described in a separate document.
These requirements belong to the U.S. system; Korean standards should be confirmed directly with the relevant authorities and the treating institution. (Source: FDA, HCT/P donor testing: specific requirements)

In consultation, ask about three points: what donor eligibility, screening, or testing information can be provided for this material; how far processing and storage information can be confirmed; and whether that content is provided in writing. The difference between a place that answers specifically and a place that moves on with "validated material" shows up here.

Write the answers next to the product name on your notes: what was shared, what was said to be unavailable, and whether a written summary will be given the same day. "We use trusted suppliers" is not the same as naming which screening or testing categories are documented for this lot.

4. Keep labels and lot traceability records

What remains after the procedure is the record. When you later consult elsewhere or need to describe symptoms, a record makes the conversation precise.

Confirm five items: product name, manufacturing or supply information, lot or traceability identifiers, date of use, and treatment areas. Record format and how much is shared vary by material and institutional process, so ask in advance how far you can receive them.

After the procedure, keep four things — a copy of the consent form, any handouts you received, confirmation details for the material used, and aftercare contact information. Store these four in one place.

If you travel or change clinics within a few months, those four items are often more useful than a verbal summary of "which skin booster." A lot number and area map travel better across languages and providers than a brand nickname alone.

5. What to actually read on the consent form

When you scan the consent form before signing, the places to look are fixed. Rather than reading every line once, it is more efficient to check that the items below do not contradict each other.

Check item	Cross-check against what you heard in consultation
Exact product name	Does it match the product name in the verbal explanation?
Source-material origin	Is human dermal origin stated?
Treatment areas and purpose	Does it match this plan?
Known risks and limits	Does it match the range explained to you?
Alternatives	Were other options also explained?
Contact criteria if something is off	Are contact details and after-hours routes written?

If a phrase on the consent form is vague, ask on the spot what that phrase means for this product and this application. That is much simpler than asking after you sign.

Also check whether the consent form lists a product family only, or the exact trade name that will appear on the lot label. Family-only wording is a reason to pause and realign the paperwork before signature—not a detail to "sort out later."

6. Post-procedure observation and contact criteria

If pain, swelling, heat, or redness worsens after the procedure, or if you see discharge, blistering, or a spreading rash outside the range you were told to expect, contact the treating clinic. General observation points are on our treatment safety page.

Receive contact criteria split by time axis so they are usable. Write three windows: what to check the same day, what to watch over the next few days, and what still present later should prompt a call. Gaps in the explanation show up immediately when you write them this way.

Save the after-hours route next to the three windows. When a change appears in the evening, you should not have to search the website again for how to reach the clinic.

7. Consultation checklist for human dermal–derived materials

□ Did you confirm the exact product name and manufacturing or supply information
□ Is human dermal (hADM) origin stated in writing
□ Did you ask how far donor screening and testing information can be provided
□ How far can processing and storage information be confirmed
□ Can you receive lot or traceability identifiers
□ Do treatment areas and purpose match this plan
□ Did you also hear about other available options
□ Are contact criteria and after-hours routes on the document
□ Did you store the consent copy · handouts · material details · contact information

Bring this checklist on paper or on your phone. An empty box is a reason to ask again before you leave—not something to fill later from marketing pages.

Frequently asked questions

Q1. Are Re2O and DermaCell the same thing?

Both are skin-booster–line options that use human dermal (hADM)–derived components, but they are not the same product. Manufacturing and supply, processing methods, and intended use can differ by product, so confirm each one against the exact product name and the documents provided.

Q2. How do they differ from autologous procedures (SVF · PRF)?

The largest difference is that the source material is not your own. That adds confirmation items for donor screening and testing, processing and storage, and lot traceability. Conversely, there is no harvest of your own tissue such as a fat harvest.

Q3. Do all human tissue–derived materials follow the same oversight system?

Material, processing, product classification, and intended use can differ. The U.S. FDA handles such materials in the HCT/P category, but authorization and availability in Korea should be confirmed separately with Korean official information and the actual product documents.

Q4. If donor screening information is available, can I feel fully at ease?

Screening and testing information concerns procedures meant to reduce risk; individual allergy history, past adverse reactions, and current health still need separate review. Confirming both layers with the clinical team is more accurate.

Q5. Which records should I keep after the procedure?

Keep four items: a copy of the consent form, handouts you received, confirmation details for the material used, and aftercare contact information. They help you describe symptoms or questions accurately later.

Consultation information

Cellinique Clinic is at Yeonseung Building, 228 Dosan-daero, Gangnam-gu, Seoul — about a 10-minute walk from Apgujeong Station or Hakdong Station. Medical Director Dr. Kim Gun-woo handles consultation, treatment, and aftercare directly. Suitability and composition for Re2O and DermaCell are confirmed individually in consultation.

This article is general information and does not replace medical care. Diagnosis and plans suited to your condition should be confirmed in consultation.